Increasing prevalence of epilepsy worldwide is expected to drive the demand for epilepsy treatment drugs. Additionally, technological advancements in drug delivery systems and the introduction of novel therapies are further expected to boost market growth. Moreover, growing awareness about epilepsy and its treatment options among patients and healthcare providers is likely to contribute to market expansion.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Drug Class, Type, Route Of Administration, Age Group, Seizure Type, Distribution Channel, |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | UCB Pharma S.A., GlaxoSmithKline Plc, Sanofi, SK Biopharmaceuticals, Eisai, Novartis AG, Novel Laboratories, Pfizer, Neurelis,, Bausch Health Companies, Dr. Reddy's Laboratories, Sumitomo Pharma, Jazz Pharmaceuticals,, Sun Pharmaceutical Industries. |
High costs associated with epilepsy treatment drugs and limited access to healthcare in developing regions are major restraints for the epilepsy treatment drugs market. Furthermore, stringent regulatory requirements for drug approval and the presence of alternative treatment options such as surgery and medical devices pose challenges for market growth.